Health Care & Life Sciences » Pharmaceuticals | Botanix Pharmaceuticals Ltd.

Botanix Pharmaceuticals Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
692.50
-
-
-
-
Gross Income
692.50
-
-
-
-
SG&A Expense
1,577.60
452.90
267.10
4,806.20
12,940.80
EBIT
2,270.10
452.90
267.10
4,806.20
12,940.80
Unusual Expense
1,053.70
-
1,399.50
-
-
Non Operating Income/Expense
30.50
117.60
41.80
-
190.00
Interest Expense
1.30
-
-
3.20
2.50
Pretax Income
1,231.30
527.40
1,708.40
4,762.90
12,644.70
Income Tax
100.30
-
-
-
1,632.90
Consolidated Net Income
1,131.00
527.40
1,708.40
4,762.90
11,011.80
Net Income
1,131.00
527.40
1,708.40
4,762.90
11,011.80
Net Income After Extraordinaries
1,131.00
40.40
1,708.40
4,762.90
11,011.80
Net Income Available to Common
1,131.00
1,014.50
1,708.40
4,762.90
11,011.80
EPS (Basic)
0.03
0.01
0.01
0.01
0.02
Basic Shares Outstanding
37,321.60
77,339.00
157,746.30
434,195.50
488,096.90
EPS (Diluted)
0.03
0.01
0.01
0.01
0.02
Diluted Shares Outstanding
37,321.60
77,339.00
157,746.30
434,195.50
488,096.90
EBITDA
2,270.10
-
267.10
4,806.20
-
Non-Operating Interest Income
16.80
43.10
-
46.50
88.20

About Botanix Pharmaceuticals

View Profile
Address
50 Angove Street
North Perth Western Australia (WA) 6006
Australia
Employees -
Website http://www.botanixpharma.com
Updated 07/08/2019
Botanix Pharmaceuticals Ltd. engages in the development of next generation therapeutics for the treatment of skin diseases. It focuses on the treatment of patients battling with acne, psoriasis, and atoptic dermatitis. The company also develops pharmaceutical ingredient known as cannabidol, which seeks to treat epilepsy, pain, arthritis, and schizophrenia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.